<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ni J</submitter><funding>Shanghai Action Plan for Science, Technology and Innovation</funding><funding>Shanghai Oriental Talent Program (Outstanding Project)</funding><funding>Noncommunicable Chronic Diseases-National Science and Technology Major Project</funding><funding>Shanghai Leading Talent Program of Eastern Talent Plan</funding><funding>Three-year Action Program of Shanghai Municipality for Strengthening the Construction of the Public Health System</funding><pagination>434-442</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12673452</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(1)</volume><pubmed_abstract>&lt;h4>Aims&lt;/h4>Serum 1,5-anhydroglucitol (1,5-AG) indicates glycemic control over 1-2 weeks and is particularly useful for monitoring postprandial hyperglycemia. However, its predictive value for long-term outcomes in type 2 diabetes has not been fully established. Therefore, our study intends to examine the correlation between 1,5-AG and risk of all-cause and cardiovascular mortality.&lt;h4>Methods&lt;/h4>In this real-world cohort study, 3721 patients with type 2 diabetes were classified by 1,5-AG levels (&lt;6.0 and ≥6.0 μg/mL). Cox proportional hazards regression models served to analyse the link between 1,5-AG levels and risk of all-cause and cardiovascular mortality, while restricted cubic splines were employed to investigate linearity of this association.&lt;h4>Results&lt;/h4>Across a median 7.4-year</pubmed_abstract><journal>Diabetes, obesity &amp; metabolism</journal><pubmed_title>Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study.</pubmed_title><pmcid>PMC12673452</pmcid><funding_grant_id>GWVI-11.2-YQ07</funding_grant_id><funding_grant_id>LJ2024121</funding_grant_id><funding_grant_id>GWVI-11.1-49</funding_grant_id><funding_grant_id>23JS1401000</funding_grant_id><funding_grant_id>2024ZD0532001</funding_grant_id><funding_grant_id>2024ZD0532000</funding_grant_id><pubmed_authors>Ni J</pubmed_authors><pubmed_authors>Lu W</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Chen L</pubmed_authors><pubmed_authors>Lu J</pubmed_authors><pubmed_authors>Cai J</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Su H</pubmed_authors><pubmed_authors>Xia T</pubmed_authors><pubmed_authors>Zhou J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study.</name><description>&lt;h4>Aims&lt;/h4>Serum 1,5-anhydroglucitol (1,5-AG) indicates glycemic control over 1-2 weeks and is particularly useful for monitoring postprandial hyperglycemia. However, its predictive value for long-term outcomes in type 2 diabetes has not been fully established. Therefore, our study intends to examine the correlation between 1,5-AG and risk of all-cause and cardiovascular mortality.&lt;h4>Methods&lt;/h4>In this real-world cohort study, 3721 patients with type 2 diabetes were classified by 1,5-AG levels (&lt;6.0 and ≥6.0 μg/mL). Cox proportional hazards regression models served to analyse the link between 1,5-AG levels and risk of all-cause and cardiovascular mortality, while restricted cubic splines were employed to investigate linearity of this association.&lt;h4>Results&lt;/h4>Across a median 7.4-year</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-07T04:43:44.071Z</modification><creation>2026-06-07T03:07:08.972Z</creation></dates><accession>S-EPMC12673452</accession><cross_references><pubmed>41090407</pubmed><doi>10.1111/dom.70214</doi></cross_references></HashMap>